Effects of branched-chain amino acids (BCAAs) on the progression of advanced liver disease: A Korean nationwide, multicenter, retrospective, observational, cohort study

Jung Gil Park, Won Young Tak, Soo Young Park, Young Oh Kweon, Se Young Jang, Yu Rim Lee, Si Hyun Bae, Jae Young Jang, Do Young Kim, June Sung Lee, Ki Tae Suk, In Hee Kim, Heon Ju Lee, Woo Jin Chung, Byoung Kuk Jang, Jeong Ill Suh, Jeong Heo, Won Kee Lee

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Evidence of the potential benefits of long-term oral branched-chain amino acid (BCAA) supplementation in reducing the severity of liver disease is limited. Patients who were diagnosed with liver cirrhosis with a Child-Pugh (CP) score of 8-10 were included. The BCAA group consumed BCAAs daily for at least 6 months, and the control group consumed a diet without BCAA. We analyzed the improvements based on the model for end-stage liver disease (MELD) score, CP score, incidence of cirrhosis-related complications, and event-free survival over 2 years. Among the 867 recruited patients, 307 (166 in the BCAA group and 141 in the control group) were analyzed. The BCAA group was divided into 3 subgroups, whose patients consumed 4.15 g, 8.3 g, or 12.45 g of BCAAs daily for the analysis. There were significant differences in the CP score, albumin, and hepatic encephalopathy between the 2 groups at baseline. After matching the propensity scores, we analyzed patients in the BCAA-12.45 g group (12.45 g of BCAAs daily, n = 41) and matched control group (n = 41). The MELD score significantly improved in the BCCA-12.45 g group compared to the matched control group (P = .004). The changes in the serum bilirubin level (P = .014) and CP score (P = .033) over time also differed significantly between the 2 groups. The incidence rates of cirrhosis-related complications (P = .973) and development of hepatocellular carcinoma (2 cases each) did not differ significantly between the 2 groups. Long-term oral BCAA supplementation has beneficial effects in patients with advanced liver cirrhosis. A further large-scale prospective study is needed to delineate these beneficial effects.

Original languageEnglish
Article numbere6580
JournalMedicine (United States)
Volume96
Issue number24
DOIs
Publication statusPublished - 2017 Jun 1

Fingerprint

Branched Chain Amino Acids
Observational Studies
Liver Diseases
Cohort Studies
Control Groups
End Stage Liver Disease
Liver Cirrhosis
Fibrosis
Research Design
Propensity Score
Hepatic Encephalopathy
Incidence
Bilirubin
Disease-Free Survival
Albumins
Hepatocellular Carcinoma
Prospective Studies
Diet

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Park, Jung Gil ; Tak, Won Young ; Park, Soo Young ; Kweon, Young Oh ; Jang, Se Young ; Lee, Yu Rim ; Bae, Si Hyun ; Jang, Jae Young ; Kim, Do Young ; Lee, June Sung ; Suk, Ki Tae ; Kim, In Hee ; Lee, Heon Ju ; Chung, Woo Jin ; Jang, Byoung Kuk ; Suh, Jeong Ill ; Heo, Jeong ; Lee, Won Kee. / Effects of branched-chain amino acids (BCAAs) on the progression of advanced liver disease : A Korean nationwide, multicenter, retrospective, observational, cohort study. In: Medicine (United States). 2017 ; Vol. 96, No. 24.
@article{476846bc61544913a805ae23cb8dd02b,
title = "Effects of branched-chain amino acids (BCAAs) on the progression of advanced liver disease: A Korean nationwide, multicenter, retrospective, observational, cohort study",
abstract = "Evidence of the potential benefits of long-term oral branched-chain amino acid (BCAA) supplementation in reducing the severity of liver disease is limited. Patients who were diagnosed with liver cirrhosis with a Child-Pugh (CP) score of 8-10 were included. The BCAA group consumed BCAAs daily for at least 6 months, and the control group consumed a diet without BCAA. We analyzed the improvements based on the model for end-stage liver disease (MELD) score, CP score, incidence of cirrhosis-related complications, and event-free survival over 2 years. Among the 867 recruited patients, 307 (166 in the BCAA group and 141 in the control group) were analyzed. The BCAA group was divided into 3 subgroups, whose patients consumed 4.15 g, 8.3 g, or 12.45 g of BCAAs daily for the analysis. There were significant differences in the CP score, albumin, and hepatic encephalopathy between the 2 groups at baseline. After matching the propensity scores, we analyzed patients in the BCAA-12.45 g group (12.45 g of BCAAs daily, n = 41) and matched control group (n = 41). The MELD score significantly improved in the BCCA-12.45 g group compared to the matched control group (P = .004). The changes in the serum bilirubin level (P = .014) and CP score (P = .033) over time also differed significantly between the 2 groups. The incidence rates of cirrhosis-related complications (P = .973) and development of hepatocellular carcinoma (2 cases each) did not differ significantly between the 2 groups. Long-term oral BCAA supplementation has beneficial effects in patients with advanced liver cirrhosis. A further large-scale prospective study is needed to delineate these beneficial effects.",
author = "Park, {Jung Gil} and Tak, {Won Young} and Park, {Soo Young} and Kweon, {Young Oh} and Jang, {Se Young} and Lee, {Yu Rim} and Bae, {Si Hyun} and Jang, {Jae Young} and Kim, {Do Young} and Lee, {June Sung} and Suk, {Ki Tae} and Kim, {In Hee} and Lee, {Heon Ju} and Chung, {Woo Jin} and Jang, {Byoung Kuk} and Suh, {Jeong Ill} and Jeong Heo and Lee, {Won Kee}",
year = "2017",
month = "6",
day = "1",
doi = "10.1097/MD.0000000000006580",
language = "English",
volume = "96",
journal = "Medicine (United States)",
issn = "0025-7974",
publisher = "Lippincott Williams and Wilkins",
number = "24",

}

Park, JG, Tak, WY, Park, SY, Kweon, YO, Jang, SY, Lee, YR, Bae, SH, Jang, JY, Kim, DY, Lee, JS, Suk, KT, Kim, IH, Lee, HJ, Chung, WJ, Jang, BK, Suh, JI, Heo, J & Lee, WK 2017, 'Effects of branched-chain amino acids (BCAAs) on the progression of advanced liver disease: A Korean nationwide, multicenter, retrospective, observational, cohort study', Medicine (United States), vol. 96, no. 24, e6580. https://doi.org/10.1097/MD.0000000000006580

Effects of branched-chain amino acids (BCAAs) on the progression of advanced liver disease : A Korean nationwide, multicenter, retrospective, observational, cohort study. / Park, Jung Gil; Tak, Won Young; Park, Soo Young; Kweon, Young Oh; Jang, Se Young; Lee, Yu Rim; Bae, Si Hyun; Jang, Jae Young; Kim, Do Young; Lee, June Sung; Suk, Ki Tae; Kim, In Hee; Lee, Heon Ju; Chung, Woo Jin; Jang, Byoung Kuk; Suh, Jeong Ill; Heo, Jeong; Lee, Won Kee.

In: Medicine (United States), Vol. 96, No. 24, e6580, 01.06.2017.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Effects of branched-chain amino acids (BCAAs) on the progression of advanced liver disease

T2 - A Korean nationwide, multicenter, retrospective, observational, cohort study

AU - Park, Jung Gil

AU - Tak, Won Young

AU - Park, Soo Young

AU - Kweon, Young Oh

AU - Jang, Se Young

AU - Lee, Yu Rim

AU - Bae, Si Hyun

AU - Jang, Jae Young

AU - Kim, Do Young

AU - Lee, June Sung

AU - Suk, Ki Tae

AU - Kim, In Hee

AU - Lee, Heon Ju

AU - Chung, Woo Jin

AU - Jang, Byoung Kuk

AU - Suh, Jeong Ill

AU - Heo, Jeong

AU - Lee, Won Kee

PY - 2017/6/1

Y1 - 2017/6/1

N2 - Evidence of the potential benefits of long-term oral branched-chain amino acid (BCAA) supplementation in reducing the severity of liver disease is limited. Patients who were diagnosed with liver cirrhosis with a Child-Pugh (CP) score of 8-10 were included. The BCAA group consumed BCAAs daily for at least 6 months, and the control group consumed a diet without BCAA. We analyzed the improvements based on the model for end-stage liver disease (MELD) score, CP score, incidence of cirrhosis-related complications, and event-free survival over 2 years. Among the 867 recruited patients, 307 (166 in the BCAA group and 141 in the control group) were analyzed. The BCAA group was divided into 3 subgroups, whose patients consumed 4.15 g, 8.3 g, or 12.45 g of BCAAs daily for the analysis. There were significant differences in the CP score, albumin, and hepatic encephalopathy between the 2 groups at baseline. After matching the propensity scores, we analyzed patients in the BCAA-12.45 g group (12.45 g of BCAAs daily, n = 41) and matched control group (n = 41). The MELD score significantly improved in the BCCA-12.45 g group compared to the matched control group (P = .004). The changes in the serum bilirubin level (P = .014) and CP score (P = .033) over time also differed significantly between the 2 groups. The incidence rates of cirrhosis-related complications (P = .973) and development of hepatocellular carcinoma (2 cases each) did not differ significantly between the 2 groups. Long-term oral BCAA supplementation has beneficial effects in patients with advanced liver cirrhosis. A further large-scale prospective study is needed to delineate these beneficial effects.

AB - Evidence of the potential benefits of long-term oral branched-chain amino acid (BCAA) supplementation in reducing the severity of liver disease is limited. Patients who were diagnosed with liver cirrhosis with a Child-Pugh (CP) score of 8-10 were included. The BCAA group consumed BCAAs daily for at least 6 months, and the control group consumed a diet without BCAA. We analyzed the improvements based on the model for end-stage liver disease (MELD) score, CP score, incidence of cirrhosis-related complications, and event-free survival over 2 years. Among the 867 recruited patients, 307 (166 in the BCAA group and 141 in the control group) were analyzed. The BCAA group was divided into 3 subgroups, whose patients consumed 4.15 g, 8.3 g, or 12.45 g of BCAAs daily for the analysis. There were significant differences in the CP score, albumin, and hepatic encephalopathy between the 2 groups at baseline. After matching the propensity scores, we analyzed patients in the BCAA-12.45 g group (12.45 g of BCAAs daily, n = 41) and matched control group (n = 41). The MELD score significantly improved in the BCCA-12.45 g group compared to the matched control group (P = .004). The changes in the serum bilirubin level (P = .014) and CP score (P = .033) over time also differed significantly between the 2 groups. The incidence rates of cirrhosis-related complications (P = .973) and development of hepatocellular carcinoma (2 cases each) did not differ significantly between the 2 groups. Long-term oral BCAA supplementation has beneficial effects in patients with advanced liver cirrhosis. A further large-scale prospective study is needed to delineate these beneficial effects.

UR - http://www.scopus.com/inward/record.url?scp=85022020751&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85022020751&partnerID=8YFLogxK

U2 - 10.1097/MD.0000000000006580

DO - 10.1097/MD.0000000000006580

M3 - Article

C2 - 28614215

AN - SCOPUS:85022020751

VL - 96

JO - Medicine (United States)

JF - Medicine (United States)

SN - 0025-7974

IS - 24

M1 - e6580

ER -